Functional roles of the two ABC signature sequences ("LSGGQ") in the N-and C-terminal nucleotide binding domains of P-glycoprotein were studied by mutating the conserved Ser residues to Ala. The two single mutants (S528A; S1173A) each impaired ATPase activity mildly, and showed generally symmetrical effects on function, consistent with equivalent mechanistic roles of the two nucleotide sites. Synergy between the two mutations when combined was remarkable and resulted in strong catalytic impairment. 
P-glycoprotein (Pgp)
1 is a plasma membrane-located efflux pump which confers multidrug resistance in human cancers by virtue of its ability to exclude chemotherapeutic drugs from cells in an ATP hydrolysis-dependent manner. In recent years it has been recognized as a general mechanism for protecting the body from hydrophobic toxins, playing a particularly important role in specific tissues such as the central nervous system. Its impact on therapy for other diseases, e.g. AIDS, and its potential impact on novel drug therapies in general, have generated significant interest in studies of its structure and mechanism, with the underlying aims of understanding its physiological function and development of new strategies for circumventing or disabling the protein (1) (2) (3) (4) .
Pgp is a member of the ABC transporter superfamily (5) , and consists of two six-helix membrane domains and two nucleotide-binding domains (NBDs) contained in one continuous ϳ1280-residue polypeptide. The two NBDs are ϳ60% identical in sequence and each contain Walker A and B consensus sequences, both of which are known to be intimately involved in and required for the ATP hydrolysis reaction (6 -11) . Inactivation of the ATP hydrolysis reaction by mutations in these sequences leads, as one would predict, to commensurate loss of ATP-driven drug efflux from cells. Between the Walker A and B sequences is found a third conserved sequence ("LSGGQ") which is named the ABC signature sequence, because it is the hallmark of the ABC transporter superfamily (5, 12) . The very strong conservation of this sequence in evolution implies an important role, but what that role is has not yet been determined.
New ideas about the role of the ABC signature sequence have come from x-ray crystallography studies and from photocleavage and cross-linking studies. At the time of writing no highresolution structure of Pgp is available, but structures of the dimeric NBD-containing subunits of Rad50, MalK, and thermophilic MJ0796 (13) (14) (15) and of the complete ABC transporter BtuCD (16) have been published, and show a most interesting feature, which is that in the dimeric NBD arrangement seen in these structures, the ABC signature sequence of NBD2 lies juxtaposed to the Walker A sequence of NBD1, and vice versa. The two bound nucleotides (where present) are sandwiched between the Walker A and ABC signature sequences, with the hydroxyl side-chain group of the Ser residue of the ABC signature sequence coming close enough to the ␥-phosphate of ATP to possibly form an H-bond with a ␥-phosphate oxygen (13) (14) (15) . In addition, substantial conformational movement of the LS-GGQ region is hypothesized in several of these reports. Earlier photocleavage studies in MalK had determined that the Walker A and ABC signature sequences of different NBDcontaining subunits must lie close to the vanadate (V i ) trapped in the V i -ADP transition state analog complex (17) . Crosslinking studies in Pgp established that the Walker A sequence of NBD1 must lie within disulfide-bridging distance of the ABC signature sequence in NBD2 and vice versa (18) . Thus there is strong evidence that the ABC signature sequence is potentially positioned to play an important role in catalysis. One idea that comes immediately to mind is that it facilitates correct dimer interface formation between the NBDs. Our work on Pgp has indicated that correct NBD dimer formation is an integral requirement of the catalytic pathway, necessary to form the transition state after binding of drug and nucleotides (10, 19) . A second possibility is that the Ser-OH affects the chemistry of ATP hydrolysis directly by interacting with the ATP ␥-phosphate.
Previous reports described mutations of this Ser residue. It is known that cystic fibrosis patients show mutations Ser to Asn, Ile, or Arg, and that the analogous mutations, produced in the yeast ABC transporter STE6, caused substantial defects in transport function (20, 21) . In the bacterial transporter HisP, mutation of Ser to Phe also caused substantial defect in trans-port, although photolabeling of the catalytic sites was reduced by only 50% (22) . All of these previously reported mutations significantly alter the bulk and chemical nature at the Ser residue position. In Pgp, it was reported briefly that single Ser to Cys mutations in NBD1 or NBD2 of human MDR1 caused partial loss of ATPase activity (18) .
In mouse MDR3 Pgp the two relevant Ser residues are Ser 528 and Ser 1173 , in the N-and C-terminal ABC signature sequences, respectively. Mouse MDR3 Pgp is 87% identical in sequence to human MDR1 Pgp, and has the advantage that it can be prepared in very pure form on relatively large scale (23) . A further advantage of using pure protein is that for many assays the natural ligands ATP and ADP can be used to study the catalytic mechanism, thus the stoichiometry of bound intermediates, and absolute rate constants can be derived. In this study we mutated both Ser 528 and Ser 1173 to Ala, singly and in combination, to determine the importance of the ABC signature Ser hydroxyl in reaction chemistry and the importance of NBD integration into a complete dimer structure for catalysis.
EXPERIMENTAL PROCEDURES

Generation of Mutant Pgp; Expression of Mutant Pgp in Pichia pastoris;
Purification of Pgp-Mutations S528A and S1173A were generated by PCR mutagenesis of pAlt-mdr3N and pAlt-mdr3.6C (10, 24) , respectively. For the S528A mutation the primers were: Outside forward, 5Ј-GGGCACAAACCAGACAACATACAAGGAAATC; Outside reverse, 5Ј-AGCGGATAACAATTTCACACAGGA; Mutagenic forward, 5Ј-GGGGCGCAGCTGGCTGGGGGCCAGAAACAGAGAATCGC; Mutagenic reverse, 5Ј-GCGATTCTCTGTTTCTGGCCCCCAGCCAGCTGC-GCCC. For the S1173A mutation the primers were: Outside forward, CGCCAGGGTTTTCCCAGTCACGAC; Outside reverse, same as for S528A; Mutagenic forward, 5Ј-GGCACTCAGCTGGCGGGTGGGCAG-AAG; Mutagenic reverse, 5Ј-CTTCTGCCCACCCGCCAGCTGAGTTGC-CTTTGTC. The initial PCR products were blunt-end-ligated into SmaIcut pUC118, and the clones obtained were tested for presence of the mutations by DNA sequencing. Correct sequence of the whole fragment to be transferred was further validated by DNA sequencing. The mutations were then transferred into pHIL-mdr3.6-His6 (24) on an EcoR1-SmaI fragment (S528A) or SpeI-SnaB1 fragment (S1173A).
Expression of the mutant proteins in the Invitrogen P. pastoris expression system (license no. 272749) was as in Ref. 25 . Strains that showed good expression of Pgp in rapid membrane preparations (23) were saved as glycerol stocks. For purification of Pgp, cells were grown in 6-liter batches in a fermentor as described in Ref. 23 . Cell disruption was as in Ref. 10 , preparation of crude microsomes, solubilization with n-dodecyl-␤ -D-maltoside (DM), Ni-affinity chromatography, DEAE-anion exchange, and concentration by pressure filtration were as previously described (23) .
Activation of Pgp by Lipids and DTT; Centrifuge Column Elution of Pgp-For activation, Pgp was incubated with DTT (8 mM) and Escherichia coli lipid (Avanti, acetone/ether precipitated) at a final ratio of 50:1 (for ATPase measurement) or 2:1 (for trapping and photolabeling experiments) lipid/protein (w/w) for 20 min at room temperature followed by sonication for 30 s at 4°C in a bath sonicator. Centrifuge column elution of Pgp was performed exactly as in Ref. 19 . Briefly, elution was at 4°C, using 1-ml Sephadex G-50 columns equilibrated in 50 mM Tris-Cl, pH 7.5 and 0.001% DM. As noted in Ref. 19 and confirmed here, recovery of Pgp was routinely 70 -90% as judged by ATPase and/or protein assays. However, in order to reduce the amount of experimental manipulation to manageable proportions we routinely assumed a protein recovery of 80%.
Assay of ATPase Activity; Determination of K m (MgATP) and K i (MgADP) -Assays of wild-type, S528A, and S1173A Pgp were carried out using 2-5 g of protein by the linked-enzyme assay (26) or the malachite-green based colorimetric assay (27, 28) , which agreed well. Where a more sensitive assay was required (e.g. with S528A/S1173A Pgp) usually 1 g of protein was assayed by the charcoal adsorption method in combination with [␥- C]MgADP were present at 200 or 100 M, respectively with 2 mM excess MgSO 4 . After preincubation (usually 20 min at 37°C) Pgp samples were passed through centrifuge columns at 4°C to remove unbound ligands, and bound nucleotide was assayed by radioactivity counting. Stoichiometry of trapped nucleotide was calculated using a molecular mass of 142 kDa for Pgp (see also "Protein Determination" below). Release of trapped MgADP was followed by allowing the centrifuge column eluates to incubate for varied times at 37°C, before passing through a second centrifuge column to determine residual bound nucleotide. Reactivation of ATPase was followed in centrifuge column eluates after trapping in the presence of nonradioactive nucleotide by incubating at 37°C and following the increase in activity continuously in the linked enzyme assay. We have previously shown that rate of release of trapped MgADP or reactivation of ATPase is not affected by presence of verapamil or MgATP in the medium.
Protein Determination-Accurate Pgp concentration was calculated by reference to a standard pure wild-type preparation, which had been subjected to amino acid analysis. A range of amounts of pure wild-type or mutant proteins were run on 10% SDS-gels alongside this reference standard, stained with Coomassie Blue, and scanned. (The DTT concentration in the denaturing buffer was increased 4-fold to minimize presence of disulfide cross-linked Pgp, Ref. 33) . For rapid analysis during purification of Pgp the Bradford assay was used with bovine serum albumin as standard normalized to the reference Pgp standard.
Photolabeling with 8-azido-[␣-
32 P]ATP-Activated Pgp was passed through a centrifuge column (above) then 2.5-g samples were incubated with indicated concentrations of 8-azido-[␣-
32 P]ATP with 1 mM MgSO 4 and 150 M verapamil in a 50-l volume for 5 min on ice. Next, samples were irradiated for 5 min on ice at a distance of 1 cm with a short wave (254 nm) UV lamp (model UVG-11 Mineralight lamp; Ultraviolet Products; San Gabriel, CA). They were then dissolved in SDS-gel denaturing buffer and applied to SDS-gels.
Routine gels was done as previously described (10) .
Materials-NaADP was from Sigma (cat. A-2754). [8-14 C]ADP and [␣-
32 P]ATP were from PerkinElmer Life Sciences. E. coli lipids were from Avanti Polar Lipids. 8-azido-[␣-
32 P]ATP was from Affinity Labeling Technologies. Acid-washed charcoal was from Sigma (cat. C-5510).
RESULTS
General-To investigate the role(s) of the conserved Ser residues in the ABC signature sequences of NBD1 and NBD2 of mouse MDR3 P-glycoprotein (Ser 528 and Ser 1173 ) we mutated each to Ala, and then expressed the two single mutant (S528A and S1173A) and the double mutant protein (S528A/S1173A) in P. pastoris (25) . Proteins were obtained in high purity (Ͼ95%) from microsomes by a previously established procedure involving detergent solubilzation, Ni-chelate chromatography, and passage through an anion exchange column (23) . Yields of mutant proteins were the same as for wild-type mouse MDR3 Pgp. Fig. 1 shows the pure mutant proteins on SDS-gels. In order to ensure that the mutant proteins assumed a properly folded native conformation we performed a photolabeling experiment with increasing concentrations of 8-azido-[␣-
32 P]-MgATP, shown in Fig. 2 . The data show that all three mutant proteins did bind and covalently react with 8-azido-MgATP to approximately the same extent as wild type. Our previous work has shown that 8-azido-MgATP is a good analog of MgATP for hydrolysis at Pgp catalytic sites (34) .
ATPase Activity of S528A, S1173A, and S528A/S1173A Mutant Proteins-Pgp prepared by the method described above requires activation with lipid and DTT to reveal ATPase activity, and this was done as described in "Experimental Procedures." Wild-type, S528A, and S1173A MDR3 Pgp were assayed for ATPase by two procedures as described in "Experimental Procedures," the linked-enzyme assay and the malachite green assay, which gave comparable results. As shown in Table I , and in confirmation of much earlier work, wild-type Pgp ATPase activity was strongly stimulated by verapamil and the K m (MgATP) measured here was 0.34 mM. Specific ATPase activities of S528A and S1173A Pgp were both 74% of wild-type activity in presence of verapamil (Table I) . a ATPase activities were determined at 37°C by the linked enzyme assay and malachite green assays (wild-type, S528A, S1173A) or the charcoal adsorption assay (S528A/S1173A). All data are means of at least quadruplicate experiments. Variation among replicates was always Յ Ϯ5%.
b Verapamil concentration was 150 M. Degree of stimulation by verapamil is shown in parentheses.
FIG. 2. Covalent labeling of mutant Pgp by Mg-8-azido-[␣-32 P]ATP. Wild-type and mutant Pgp were incubated with increasing concentrations of Mg-8-azido-[␣-
32 P]ATP as shown, subjected to UV illumination, and run on SDS gels. The gels were stained with Coomassie Blue to ensure that equal amounts of wild-type and mutant proteins were run on the gel then dried and subjected to autoradiography. A, S528A; B, S1173A; C, S528A/S1173A; D, wild type.
ATPase of both mutant proteins was stimulated by verapamil, and respective K m (MgATP) values were 0.30 and 0.25 mM. MgADP is a competitive inhibitor of Pgp ATPase activity (35) . We carried out assays to determine K i (MgADP) values for the mutant proteins (see Fig. 3 ) and, as Table I shows, the resultant K i values for S528A and S1173A mutants (0.11 and 0.12 mM) were not significantly different from wild type (0.15 mM).
When we assayed the double mutant (S528A/S1173A) Pgp it was immediately apparent that the specific ATPase activity was very low and that a very sensitive assay would be required, therefore we used radioactive ATP (␥ -32 P-labeled) and the charcoal adsorption assay (see "Experimental Procedures"). Fig. 4 shows the data for evaluation of specific activity and K m (MgATP) . As the upper panel (Fig. 4A) shows, the reaction was linear with time and the activity was strongly increased by verapamil. Specific ATPase activity of the double mutant in presence of verapamil was only 3.6% of wild type (Table I) . K m (MgATP) in the double mutant had risen to 0.80 mM (Fig. 4B and Fig. 3C and Table I ). Because for technical reasons the maximal MgATP concentration that could be used was 3 mM, the K m (MgATP) of the double mutant enzyme might be somewhat underestimated.
Summarizing the ATPase data, each single mutation impaired ATPase activity mildly, without affecting apparent affinity for either MgATP or MgADP, and without affecting func- (36) and a natural pentacovalent phosphorus transition state (37) have been documented by x-ray crystallography. In Pgp, V i inhibits ATPase activity potently by trapping MgADP tenaciously at a stoichiometry of one mol/mol Pgp, and it was mainly the early work with V i (29, 30) , together with studies of covalent labeling and inhibition of Pgp by N-ethylmaleimide and NBD-chloride (28, 34, 38), and mutagenesis data (6, 7) , that led to formulation of the alternating sites catalytic mechanism of Pgp (39) . Data from many laboratories have since indicated that formation of the chemical transition state (indicated by V i -trapping of MgADP) requires that both NBDs be intact, and we have proposed that the transition state involves side-chain interactions from both NBDs acting together as a unit and occurs only after dimerization of the NBDs (10, 19) . Given the finding (above) that the two Ser to Ala mutants were much more effective in combination than singly in impairing ATPase activity, and the x-ray crystallography information from other ABC transporters showing the location of the Ser hydroxyls very close to the ␥-phosphate of ATP (see the Introduction), we next studied extensively interactions of the mutant proteins with V i .
Initial data showed that when the three mutant proteins were preincubated with 200 M MgATP and 200 M V i for 20 min at 37°C their ATPase was strongly inhibited (Ͼ90%). Using [␣-
32 P]ATP we found that approximately one mol of nucleotide/mol Pgp became trapped under these conditions in all three mutant proteins, and that the trapping was promoted by presence of verapamil (150 M) (Fig. 5A ). There was no trapping in absence of V i . We next measured the time-course of trapping of [␣-
32 P]ADP-V i complex, shown in Fig. 6A . This experiment was performed at 23°C in order to slow the reaction and allow accurate measurement. Half-times for formation of the trapped complex are shown in Table II , column 2. It is evident that, in this respect, the wild-type and mutant proteins were not markedly different. Time courses of release of trapped V i -ADP complex were then measured (Fig. 6B) and whereas all the proteins released V i -ADP following a single exponential curve, here we saw obvious differences in rates (Table II , column 3). Wild type released V i -ADP with t1 ⁄2 of 64 min (k ϭ 1.8 ϫ 10 Ϫ4 s Ϫ1 ), whereas the values for mutants were: S528A, 18 min (6.4 ϫ 10 Ϫ4 s Ϫ1 ), S1173A, 16 min (7.2 ϫ 10 Ϫ4 s Ϫ1 ), and S528A/ S1173A, 2.5 min (4.6 ϫ 10 Ϫ3 s Ϫ1 ). The two single mutant proteins released V i -ADP faster than wild type, and the double mutant released it very rapidly. Rates of reactivation of ATPase after V i -inhibition were also measured and gave t1 ⁄2 values of 69 min for wild type, 12 min for S528A, and 13 min for S1173A, corroborating the V i -ADP release data (Table II , column 4). The half-time for reactivation of ATPase of the S528A/S1173A mutant could not be accessed due to its slow turnover.
The V i concentration dependence of V i -ADP trapping is shown in Fig. 7 and concentrations of V i necessary for halfmaximal trapping (EC 50 ) are shown in Table II , column 5. These data showed that the single mutants resembled wild type, but that the double mutant required a higher concentration of vanadate in order to trap the V i -ADP complex. In parallel we also carried out assays of the V i concentration dependence of inhibition of ATPase activity. We show an example of these assays in Fig. 8, A and B (open symbols) . Concentrations of V i required to bring about half-maximal inhibition of ATPase (IC 50 ) are shown in Table II , column 6. Therefore, again, the single mutants were more similar to wild type, but the double mutant required significantly higher concentration of V i to achieve the effect. Finally we assayed formation of the V i -ADPtrapped species after incubation with V i and [8- 14 C]MgADP. In wild-type mouse MDR3 Pgp this reaction is known to be relatively slow and notably drug-dependent (19) . Fig. 9A shows the data obtained with the mutant proteins after preincubation with V i and [8- 14 C]MgADP for 120 min at 37°C. Both single mutants trapped V i -ADP in this experiment in drug-dependent fashion. The stoichiometry of trapping for wild-type and S528A was close to 1 mol/mol, with S1173A the stoichiometry was higher, close to 1.4 mol/mol. However the S528A/S1173A mutant showed significantly lowered stoichiometry of bound V i -ADP. This last result is consistent with the notably fast rate of V i -ADP release in the double mutant (Fig. 6B) together with the slow rate of formation of trapped V i -ADP from V i plus MgADP.
Taken together the results show that the single mutants did not deviate substantially in behavior from the wild-type, whereas the double mutant did, notably in its severely reduced ability retain bound V i -ADP complex in catalytic sites.
Studies with Beryllium Fluoride-Beryllium fluoride (BeFx) inhibits many ATPase enzymes. Like V i , it inhibits by trapping ADP in the catalytic site(s), but because the electronic structure of the Be atom is insufficient to form a trigonal bipyramidal structure, the trapped complex resembles the bound ATP ground state rather than the transition state (see e.g. the tetrahedral BeFx-inhibited structure of myosin as revealed by x-ray crystallography in Ref. 40) . Pgp is strongly inhibited by BeFx, which, like V i , causes trapping of BeFx-ADP at a stoichiometry of 1 mol/mol Pgp (31, 32) . Therefore it was valuable to study the effects of BeFx in the mutants, to compare with the effects of V i .
Initial experiments showed that the ATPase activity of all three mutants was inhibited by BeFx. IC 50 values for BeFx inhibition of ATPase were similar in the mutant and wild-type proteins (Table II, column 6 , see a typical experiment in Fig. 8) . Preincubation with BeFx and [␣-
32 P]MgATP for 20 min at 37°C led to trapping of the BeFx-ADP complex as shown in Fig.  5B . Here both of the single mutant proteins showed stoichiometry of trapping somewhat higher than 1 mol/mol, and the double mutant protein trapped 0.9 mol/mol. (Reasons for the higher than stoichiometric trapping of nucleotide under these conditions were not further investigated here, but are of interest for future work.) No trapping was seen in absence of BeFx. Rate of release of trapped BeFx-ADP complex was measured in Fig. 10 . Here the interesting result was that the half-times for release of the trapped BeFx-ADP complex were significantly longer in the mutants than in wild-type (Table II , column 7), in the order S528A/S1173A Ͼ S1173A Ͼ S528A Ͼ wild-type. It should also be noted that the release of BeFx-ADP followed in all cases a single exponential curve. When the mutant proteins were preincubated with [8- 14 C]MgADP and BeFx for 120 min at 37°C, trapping of BeFx-ADP complex occurred in drug-dependent fashion as with wild-type protein (Fig. 9B) . Stoichiometry of trapped nucleotide in these experiments was 1.2 mol/ mol in wild type and ranged from 0.7 mol/mol to 1.1 mol/mol in the mutants.
The BeFx experiments therefore showed some clear differences from the V i experiments. Rate of release of trapped BeFx-ADP complex was slower in the mutants as compared with wild type, whereas release of trapped V i -ADP was faster in the mutants than in wild type. IC 50 values for BeFx did not vary among the mutants and wild-type, whereas the IC 50 value for V i was notably elevated in the double mutant. On the other hand, drug stimulation of trapping was evident in experiments with both BeFx and V i , and did not vary between mutants and wild type.
DISCUSSION
General-This work was aimed at understanding the role(s) of the conserved Ser residues in the ABC signature sequences of Pgp. In the Introduction we discussed reasons why, on basis of recent x-ray structural analyses and biochemical experimentation in Pgp and other ABC transporters, one may hypothesize that these conserved Ser residues play a direct role in ATP hydrolysis reaction chemistry, and/or promote reaction by facilitating an exact fit between NBDs and nucleotides at the NBD dimer interface. Here we mutated the two Ser residues (Ser 528 and Ser 1173 to Ala, singly and in combination) to test the hypothesis. Tables I and  II that the single mutations S528A and S1173A had the same effects on catalysis. This symmetrical behavior between equivalent mutations in the N-and C-terminal nucleotide binding domains of Pgp confirms a consistent pattern that we have remarked previously (10, 24) , which strongly suggests that the two nucleotide binding domains function equivalently in catalysis. This supports a mechanism of Pgp catalysis involving alternation of equivalent catalytic sites (Refs. 39 and 41, see also Refs. 42 and 43). We note that our conclusions are based primarily upon measurements using the natural ligands MgATP and MgADP.
Symmetrical Effects of the Single Mutations and Synergy between Them in Combination-It is evident from
Whereas each single Ser to Ala mutation reduced ATPase Table  II , column 1. B, mutant and wild-type proteins were incubated with V i and [␣-
32 P]MgATP as described in Fig. 5A , passed through centrifuge columns to remove unbound ligand, then incubated at 37°C for various intervals before being passed through a second centrifuge column to assay amount of radioactive nucleotide remaining bound. Half-times for release of trapped V i -ADP are given in Table II , column 2. (E), Wildtype; (q), S528A; (OE), S1173A; (f) S528A/S1173A. activity by 26%, the combined effect in the double mutant was to reduce ATPase by 97% (Table I) . A strong synergy between the mutations was evident, therefore, pointing to a role of the conserved Ser residues in promoting efficient cooperativity between the two NBDs. This is clearly compatible with a role in promoting a strong structural fit between nucleotides and NBDs at the dimer interface. Thus, the single mutations would partly hinder formation of the catalytically productive NBD dimer, whereas the double mutation would strongly hinder it. This is the first instance in which such a synergy between equivalent mutations in NBD1 and NBD2 has been seen in Pgp.
Effects on Nucleotide Binding Affinity and Communication between Catalytic Sites and Drug-binding Sites-As judged from K m (MgATP) and K i (MgADP) values in Table I , and the photolabeling in Fig. 2 , the single mutations had no effect on affinity for nucleotides. The Ser-OH is not therefore important in directly binding the nucleotides in the ground states. The double mutation increased K m (MgATP) somewhat, possibly implying that binding of MgATP was weakened, but this conclusion is tempered by the photolabeling experiment in Fig. 2 , where no difference in 8-azido-MgATP covalent labeling was seen. Together the data indicate that the strong impairment of ATP hydrolysis is due to effects occurring after the MgATP binding event. K i (MgADP) was not significantly changed in the double mutant, showing no large increase in affinity for MgADP. The large impairment of ATP hydrolysis is therefore not likely due to impaired release of product MgADP. In none of the mutants was the degree of verapamil-stimulation of ATPase activity impaired, nor was the verapamil-stimulation (Table II) . However rate of release of the V i -ADP complex once formed occurred faster (by 4-fold in the single mutants, and much faster (by 26-fold) in the double mutant, when measured directly by radioactivity release. Assays of reactivation of ATPase after V i -inhibition corroborated these data (Table II) . This further demonstrates that impairment of ATP hydrolysis by the mutations is not due to retention of product ADP. Rather it shows that the ability of the mutants to make a stabilizing bond or bonds with the transition state is reduced. EC 50 values for V i -ADP trapping and IC 50 values for the inhibition of ATPase by V i were not notably different between the single mutants and wild-type but both parameters were markedly increased in the double mutant, again implying a reduced ability to interact with the chemical transition state, specifically with the ␥-P/P i (V i ) moiety.
BeFx also inhibited ATPase activity of the mutants and caused trapping of BeFx-ADP, but with some clear differences from V i . IC 50 values for BeFx were the same in all three mutants as in wild type (Table II) indicating that affinity for BeFx was unaltered by the mutations. Trapping of BeFx.ADP complex did occur, from either ATP or ADP (Figs. 5 and 9) but rates of release of the BeFx-ADP complex, once formed, were slower in the mutants than in wild type, suggesting a somewhat stronger interaction with the ATP-like ground state complex in the mutants. The double mutant showed the largest effect. It may be noted that the two single mutations S528A and S1173A did produce somewhat different effects on release of trapped BeFx.ADP complex (t1 ⁄2 of 38 min versus 53 min, Table  II , column 7). This might be taken as evidence of some asymmetry between the two NBDs. However, given the similarity of effects on other parameters, it is correct to say that the mutations had generally symmetrical effects.
Conclusions-1) Generally symmetrical effects of single Ser to Ala mutations in the N-and C-terminal ABC signature motifs of Pgp were seen. The single mutants impaired function (ATPase) mildly. 2) Synergy between the two mutations when combined was remarkable, resulting in strong functional impairment.
3) The Ser residues are not involved significantly in MgATP or MgADP binding, or in interdomain communication between catalytic sites and drug-binding sites. Enhanced stabilization of the MgATP-bound ground state, evidenced by BeFx-ADP retention in the mutants, might be responsible to minor degree for reduced turnover rate. Retention of product MgADP is not the cause of reduced turnover. 4) Mutation of Ser to Ala reduces the strength of interaction with the chemical transition state complex specifically. The observed reduction of ATPase rate most likely results from destabilization of the transition state. The Ser hydroxyl may interact with the bound transition state complex directly and significantly. 5) The transition state complex may form only in the dimerized NBD intermediate state, as discussed in the Introduction. Alternatively, therefore, one could conclude that the presence of both Ser-OH facilitates correct formation of the NBD dimer. This scenario is favored by the synergy between the C-and Nterminal Ala mutations. Conclusions 4 and 5 are not mutually exclusive.
